Sponsored by:

Nuclear Medicine: Page 217

Novel tracer shows early promise for brain tumor imaging
By Wayne Forrest
Tuesday, November 29 | 11:40 a.m.-11:50 a.m. | SSG08-08 | Room S504CDIn this scientific paper presentation, researchers from Washington University School of Medicine will present their work on a novel synthesized tracer that so far has shown promising tumor imaging properties in the potential to complement MRI for evaluating patients with primary and metastatic brain tumors.
November 7, 2011
Ga-68 DOTA-NOC tops F-18 DOPA-PET/CT for neuroendocrine tumors
By Wayne Forrest
Tuesday, November 29 | 10:50 a.m.-11:00 a.m. | SSG12-03 | Room S505ABIn a comparison with F-18 DOPA-PET/CT, gallium-68 (Ga-68) DOTA-NOC achieved "superior sensitivity" with neuroendocrine tumors, prompting researchers to conclude that Ga-68 DOTA-NOC could help direct more effective patient treatment.
November 7, 2011
Researchers look for link between veterans' motor issues and brain injuries
By Wayne Forrest
Monday, November 28 | 3:20 p.m.-3:30 p.m. | SSE19-03 | Room S505ABWith the help of FDG-PET, researchers at the University of Washington are investigating a possible link between Parkinsonian motor symptoms and blast-related mild traumatic brain injury among Iraq and Afghanistan war veterans.
November 7, 2011
FDG-PET/CT shows steroid therapy impact on pulmonary nodules
By Wayne Forrest
Monday, November 28 | 11:40 a.m.-11:50 a.m. | SSC14-08 | Room S505ABA pilot study at Children's Hospital of Michigan is seeking to determine whether 40 hours of steroid therapy can help characterize equivocal pulmonary nodules in FDG-PET/CT scans.
November 7, 2011
Study questions SUVmax role in solitary pulmonary nodule malignancy
By Wayne Forrest
Monday, November 28 | 11:20 a.m.-11:30 a.m. | SSC14-06 | Room S505ABResearchers at Thomas Jefferson University are challenging the traditional belief that a decrease in glucose metabolism demonstrated by a solitary pulmonary nodule during the delayed phase of dual-point FDG-PET/CT indicates that the nodule is benign.
November 7, 2011
Novel molecular imaging technique could help prostate cancer patients
By Wayne Forrest
Monday, November 28 | 11:20 a.m.-11:30 a.m. | SSC09-06 | Room S504CDIn this paper presentation, Dutch researchers will show early promising results for two novel molecular imaging techniques to detect and manage lymph node metastases in prostate cancer patients.
November 7, 2011
FDG-PET/CT predicts early response to chemo in NSCLC patients
By Wayne Forrest
Monday, November 28 | 11:00 a.m.-11:10 a.m. | SSC14-04 | Room S505ABFDG-PET/CT is showing its prowess in predicting non-small cell lung cancer (NSCLC) tumor metabolic response and length of survival one and five weeks after the start of chemotherapy treatment.
November 7, 2011
Breast imaging benefits from both PET/CT and PET/MRI
By Wayne Forrest
Sunday, November 27 | 11:05 a.m.-11:15 a.m. | SSA18-03 | Room S505ABBreast imaging can benefit from contrast-enhanced PET/CT, and even better results can be achieved with PET/MRI, according to a study by researchers from Kochi University Hospital in Japan.
November 7, 2011
USP adopts PET drug standards
By AuntMinnie.com staff writers
The U.S. Pharmacopeial Convention (USP) has adopted new quality assurance standards for compounding, producing, and researching PET drugs.
November 6, 2011
PETNet inks pact with Lilly for Amyvid radiotracer
By AuntMinnie.com staff writers
Siemens Healthcare subsidiary PETNet Solutions has signed an agreement with Eli Lilly to manufacture and distribute Lilly's molecular PET imaging agent Amyvid (florbetapir) in the U.S.
November 6, 2011
NorthStar inks NNSA deal for Mo-99
By AuntMinnie.com staff writers
NorthStar Medical Radioisotopes has signed a $4.6 million agreement with the National Nuclear Security Administration (NNSA) to advance the development of its technology to produce molybdenum-99 (Mo-99) in the U.S. without highly enriched uranium.
November 3, 2011
GE expects gains in molecular imaging
By AuntMinnie.com staff writers
GE Healthcare is looking to double the current annual sales of $2.4 billion in its molecular imaging business segment in the next three to five years.
November 3, 2011
Previous Page
Page 217 of 440
Next Page